|Day Low/High||18.35 / 18.43|
|52 Wk Low/High||14.61 / 23.50|
Strong drug sales allow the German group to increase its full-year earnings forecast, while wilting crop science revenue pose more questions about the wisdom of buying Monsanto.
U.K. lender Lloyds falls after a third-quarter profit miss, while luxury goods maker Kering surges.
This is new doctrine having to do with innovation and the stifling of innovation to create new products.
The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.
Results have shown that many major "blockbuster" deals aren't blockbuster investments later.
Regulatory issues will weigh on this deal, because of populist politics.
Forward-looking purchasing managers' indices and earnings from beleaguered lender Deutsche Bank feature among the other release highlights.
Here is why CBS, Constellation Brands, Monsanto and Aetna will be winners in 2017.
Experts say mutual funds' stakes across an industry can thwart competition and that anti-trust regulators should require them to pare their holdings in that case.
Buy mutual funds and exchange-traded funds that buy shares of those companies involved in takeovers.
Conditions seem ripe for continued upward momentum in stocks, as long as the Federal Reserve or unexpected shocks don't get in the way.
CEO Werner Baumann increases sales and margin forecasts for pharmaceuticals and insists Monsanto deal will deliver growth and improved profit.
Despite intense opposition from farm groups and skepticism from government enforcers, the merging crop technology giants say they expect to win approval by end of 2017.
Another selloff on commodity markets on Wednesday contributed to stock losses throughout the day.
Stocks lose highs by mid-afternoon Wednesday as a selloff in crude resumes.
German Dax leads the board with 0.4% gain.
Stocks add to slight gains on Wednesday as Wall Street stabilizes after three days of extreme swings.
U.S. stocks gained steam on Wednesday, even though oil prices continued to slide.
Stock futures edge higher on Wednesday as Wall Street appears to stabilize after three days of extreme swings.
The agreement values the world's biggest seed maker at $128 per share and comes with a promise of $1.5 billion of annual synergies.
Bayer has agreed to purchase Monsanto for $66 billion, or $128 a share, a 20% premium over its previous closing price.
U.S. stock futures point to a slight rebound for Wall Street on Wednesday; report says Bayer to announce acquisition of Monsanto; Wells Fargo CEO John Stumpf says he won't resign.
Monsanto shares should rise if the $129-per-share deal, including a massive break fee, is confirmed, while Bayer investors appear unsure whether to celebrate or mourn.
Zoetis is selling a lineup of drugs for dogs, and that looks to mean big business.
Zoetis is not averse to a little noise as investors, analysts take notice.
Bayer (BAYRY) is reportedly exploring a sale of its dermatology business, which has been valued at $1.1 billion, as it continues to pursue the acquisition of Monsanto (MON).
Bayer increases its latest offer to buy Monsanto, as regulators look closely at agribusiness mergers.
Bayer increases its latest offering to entice Monsanto, as regulators look closely at agribusiness mergers.
Weaker chances of a rate hike when the Federal Reserve meets in two weeks left Wall Street in a bright mood on its return from the long Labor Day weekend.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.